Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Gains from Investment Securities (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Gains from Investment Securities for 3 consecutive years, with $226682.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $226682.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $260199.0, a 258.13% increase, with the full-year FY2024 number at $2000.0, up 101.25% from a year prior.
  • Gains from Investment Securities was $226682.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $18000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $721592.0 in Q2 2023 to a low of -$865743.0 in Q3 2023.
  • A 3-year average of $100534.4 and a median of $16758.5 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 16651.82% in 2024, then tumbled 97.44% in 2025.
  • 60 Degrees Pharmaceuticals' Gains from Investment Securities stood at -$20392.0 in 2023, then surged by 176.09% to $15517.0 in 2024, then skyrocketed by 1360.86% to $226682.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Gains from Investment Securities are $226682.0 (Q3 2025), $18000.0 (Q1 2025), and $15517.0 (Q4 2024).